Cato Scholar Warns Against 'New Prohibition Panic' Over Cannabis

Cato Scholar Critiques Fear-Based Cannabis Messaging

Dr. Jeffrey A. Singer called for a shift away from prohibition-style scare tactics in cannabis policy discourse. Writing in the Chicago Tribune, Singer — a practicing surgeon and senior fellow at the Cato Institute's health policy center — said consumers are better served by transparent risk communication than by exaggerated warnings designed to discourage use. The piece arrives as the DEA's rescheduling proposal and state-level regulatory overhauls have brought cannabis harm-reduction debates back to the front page.

Singer has spent years advocating for drug-policy reform rooted in harm reduction rather than criminalization. His Tribune commentary extends that framework to the current moment, when federal agencies and state legislatures are wrestling with how to regulate a substance that remains federally controlled but is legal for adult use in 24 states.

The Case for Evidence-Based Risk Communication

Honest risk disclosure builds trust. Fear-driven messaging backfires. Singer draws parallels to alcohol and tobacco regulation, where decades of public-health campaigns have succeeded not by banning substances outright but by giving consumers clear data on dose-dependent harms. Cannabis, he contends, deserves the same treatment: labeling that discloses THC content, warnings for vulnerable populations like pregnant women and adolescents, and research-backed guidance on frequency and potency.

The surgeon's perspective comes from clinical experience. He has treated patients with cannabis hyperemesis syndrome and has seen the consequences of high-potency concentrates used without dosing literacy. But he says these harms don't justify a return to prohibition or the alarmist rhetoric that characterized the War on Drugs.

Timing: Federal Rescheduling and State-Level Tensions

The commentary lands as the DEA weighs moving cannabis from Schedule I to Schedule III. That rescheduling proposal, published in draft form in 2024 and still under administrative review, has split the policy world. Advocates see it as a long-overdue acknowledgment of medical value. Critics warn it could entrench federal control without addressing the contradictions between state and federal law.

Singer's piece doesn't take a position on the rescheduling question directly. Instead, it targets the broader information ecosystem — the press releases, op-eds, and legislative hearings that frame cannabis as either a miracle cure or a public-health catastrophe. For background on the federal rescheduling debate and its implications for state programs, see the CannIntel topic hub on the cannabis prohibition debate.

What Operators and Advocates Are Watching

Industry stakeholders say the framing battle Singer describes has real operational consequences. When state regulators adopt panic-driven policies — emergency bans on high-THC products, arbitrary potency caps, or packaging rules that treat cannabis like a hazardous chemical — compliance costs spike and legal operators lose market share to the illicit sector.

Morgan Fox, a longtime cannabis-policy advocate, has made similar arguments in recent congressional testimony. He told lawmakers that the most effective way to protect public health is to bring the unregulated market into a transparent, tested supply chain, not to impose restrictions so onerous that consumers turn back to the black market.

The Road Ahead: Policy Meets Public Perception

Singer's call for honest communication is unlikely to settle the debate, but it adds a credible medical voice to the harm-reduction camp. As federal agencies finalize rules on everything from advertising to interstate commerce, the question of how to talk about cannabis risk will shape both regulatory text and public buy-in. The stakes are high. The audience is paying attention.

Next inflection point: the DEA's final rule on rescheduling, expected later this year. If the agency moves forward with Schedule III placement, it will trigger a new round of state-level adjustments and a fresh wave of commentary on what cannabis legalization should look like in practice. Singer's argument — that consumers can handle the truth — will be tested in every statehouse and city council that writes the next generation of cannabis rules.